IDH1 and oligodendroglioma: However, EANO guidelines have suggested in 2021 that a watch-and-wait approach can be considered in grade 3 oligodendroglioma, IDH-mutant, and 1p/19q-codeleted patients with a favorable profile6 but reports of such a conservative approach are rare.